


**Supplementary figure 2: Kaplan Meier survival curves showing post-Nivo0S for gemcitabine, docetaxel and erlotinib**



Patients at risk (gem)	27	22	11	19	7	6	4	3	3	3
Patients at risk (doce)	25	21	18	12	9	5	3			
Patients at risk (erlo)	18	10	6	3	3	2	2			